Table 3. Results of six new agents in advanced NSCLC as monotherapy and in combination with platinum analogues (Pt) (10).
Agent | Complete response + Partial response | Complete response + Partial response combination with (Pt) analogues |
---|---|---|
Vinorelbine | >15% | 30-45% (C) |
Gemcitabine | >15% | 28-54% (C) |
Paclitaxel | >15% | 27-44% (C) |
Docetaxel | >15% | 25-62% (C) |
Docetaxel | >15% | 26-51% (Cb) |
Irinotecan | >15% | 50% (C) |
Pemetrexed | <15% | 30.6% (C) |